

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Currently amended) A mutant strain of mycobacterium comprising in its genome a modified tyrosine phosphatase gene ~~selected from *mptpA* bearing~~ comprising SEQ ID No. 15 ~~and *mptpB* bearing~~ SEQ ID NO. 16, the strain being incapable of expressing active tyrosine phosphatase.
2. (Currently amended) A ~~strain as claimed in~~ The mutant strain of claim 1, wherein the mycobacterium ~~strain is of a species~~ selected from the [[a]] group consisting of *M. tuberculosis* and *M. bovis*.
3. (Currently amended) A recombinant vector comprising ~~a modified *mptpA* gene~~ bearing SEQ ID NO. 15.
4. (Currently amended) A recombinant vector as claimed in claim 3, wherein the vector is ~~pAK-A~~ pAkΔA.
- 5-8. (Canceled)
9. (Currently amended) The recombinant vector of claim 3, further comprising a nucleic acid encoding a second antibiotic marker ~~gene inserted in its backbone~~.
10. (Currently amended) A recombinant vector as claimed in claim 9, wherein the second antibiotic marker gene imparts resistance to ~~an antibiotic selected from~~ kanamycin or gentamycin.
11. (Currently amended) An isolated nucleotide nucleic acid sequence bearing

comprising SEQ. No. 15 and representing modified *mptpA* gene.

12. (Canceled)

13. (Currently amended) A method for developing a mutant mycobacterium strain comprising a modified tyrosine phosphatase gene in its genome, comprising the following steps:

- a. extracting genomic DNA from a mycobacterium strain,
- b. amplifying a tyrosine phosphatase gene alongwith flanking sequences using a primer designed from the genomic DNA of step (a) to obtain a DNA fragment,
- c. characterizing the fragment of step (b) by sequencing and restriction enzymatic analysis,
- d. cloning the fragment of step (b) in a non-replicative vector,
- e. modifying the fragment in the non-replicative vector of step (d) by performing a step selected from insertion, deletion mutation or substitution,
- f. inserting a first antibiotic resistance marker gene within the fragment of step (e) to obtain a non-replicative vector comprising a modified tyrosine phosphatase gene ~~selected from *mptpA* bearing comprising SEQ ID 15 or *mptpB* bearing SEQ ID 16,~~
- g. cloning of a second antibiotic resistance marker gene in the backbone of the non-replicative vector of step (f), to obtain a recombinant vector,
- h. introducing the recombinant vector of step (g) ~~to obtain~~ into a mycobacterium strain,
- i. selecting for primary recombinant mycobacterium strains using the first antibiotic resistance marker gene,
- j. culturing the primary recombinant mycobacterium strain of step (i) harboring the first antibiotic resistance marker gene,
- k. selecting for secondary recombinant mycobacterium strains of step (j) that are sensitive to the second antibiotic resistance gene present in the vector backbone[.],
- l. culturing the secondary recombinant mycobacterium strains of step (k), to obtain a recombinant mycobacterium strain harboring the modified tyrosine phosphatase

~~gene which shows defective growth in activated macrophages and animals.~~

14. (Previously Presented) A method as claimed in claim 13, wherein the mycobacterium species is selected from a group consisting of *M. tuberculosis* and *M. bovis*.

15. (Currently amended) A method as claimed in claim 13, wherein, the primer designed in step (b) is selected from any of SEQ ID NO: 1 to 4 for amplification of *mptpA* along with its flanking regions, and any of SEQ ID NO: 5 to 8 for amplification of *mptpB* alongwith its flanking regions

16. (Previously Presented) A method as claimed in claim 13, wherein the tyrosine phosphatase gene is *mptpA* gene of SEQ ID No. 11.

17. (Canceled)

18. (Currently amended) A method as claimed in claim 13, wherein step (b) the DNA fragment is a sequence bearing comprising SEQ ID No. 13.

19-20. (Canceled)

21. (Currently amended) A method as claimed in claim 13, wherein the second antibiotic marker gene imparts resistance to ~~the antibiotic~~ kanamycin.

22. (Currently amended) A method as claimed in claim 13, wherein the recombinant vector is pAK-A pAKΔA.

23. (Canceled)

24. (Previously Presented) A method as claimed in claim 13, wherein the vector is introduced by electroporation or through phages.

25. (Canceled)

26. (Currently amended) A method as claimed in claim 13, wherein in step (k) the secondary recombinant mycobacterium strain is ~~resistant to hygromycin or chloramphenicol but sensitive to the second antibiotic kanamycin.~~

27. (Currently amended) A primer comprising SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4 sequence adapted for amplification of *mptpA* gene selected from any of SEQ ID No. 1 to 4 alongwith its flanking regions.

28. (Canceled)

29. (New) The mutant strain of claim 1, wherein the modified tyrosine phosphatase gene *mptpA* consists of SEQ ID NO:15.

30. (New) The recombinant vector of claim 3, consisting of SEQ ID NO:15.

31. (New) The primer of claim 27, consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4.